Evonik Puts Its Art on the Block While the Market Reprices the Standalone Story
Published on 11/22/2026 at 15:32 | Editorial boerse-global.deEvonik is parting with a substantial slice of its corporate art collection, with ten major works slated to go under the hammer on 2 December and online auctions planned for a further 450 pieces, according to Tagesschau. The disposal is a quiet piece of housekeeping next to the louder question now facing the specialty chemicals group: what its shares are worth without a takeover premium attached.
That question moved to the front of the agenda after BASF walked away on Thursday, having seen two non-binding all-cash offers rejected by Evonik. The most recent of those proposals stood at 24 euros per share. BASF said it pulled out because the opportunities and risks of a standalone Evonik did not justify a higher valuation, and it had weighed a further moderate increase before deciding a richer price was not in its own shareholders' interest.
The retreat leaves the rejected bids without much value as a floor for the stock. Interim Evonik chief Claus Rettig told Reuters on Thursday that the plan for the coming years is in place and that the company can develop under its own steam now that BASF has stepped back. He also said the withdrawal removes an uncertainty for employees and lets the group concentrate on its independent development.
Oddo Trims Its View
Analysts moved quickly. Oddo BHF cut Evonik from "Outperform" to "Neutral" on Friday, pointing to the end of the takeover efforts, and lowered its price target to 19 euros from 22. The shares closed Friday at 18.18 euros, below the revised marker.
Should investors sell immediately? Or is it worth buying Evonik?
For investors, the comparison with a single analyst target says little on its own. What matters is whether the operating business can justify the market value without the prospect of a BASF deal. Focusing on the standalone business is, for now, a statement about direction rather than about future results.
The bullish case rests on Evonik being able to hold out the prospect of better earnings under its own power and to explain credibly what operational progress will deliver them. The more concretely the company ties that story together, the more willing investors may be to grant the stock a higher rating even with no bid on the table.
The risk runs deeper than a missing positive catalyst. Should earnings prospects deteriorate, shareholders would have to mark down their assumptions about Evonik's worth as an independent company.
Evonik at a turning point? This analysis reveals what investors need to know now.
A New Forecast as the Yardstick
Until Evonik demonstrates operational progress that points to better results, headroom for a higher valuation remains largely a scenario. If the company does underpin an improved earnings outlook, the standalone case gains weight. A weaker forecast would likely make the gap to the price target a secondary concern for investors. That makes a new or updated earnings guidance the next concrete test — the measure by which the market can judge whether operations can support a richer valuation.
Meanwhile, the RAG-Stiftung intends to reduce its stake in Evonik step by step to 25.1% even after BASF's exit, Reuters reported. The foundation expressed regret that BASF ended its takeover efforts without deeper exploratory talks.
Ad
Evonik Stock: New Analysis - 22 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
